Other Information
−Removed: During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the six months ended June 30, 2024, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: On July 23, 2024, we announced the closing of the sale of our Lexington Facility to Genezen, and on August 1, 2024, we announced an organizational restructuring.
+Added: The restructuring and the Lexington Facility sale together were the outcome of a recently completed, comprehensive review of our operations with the goals of conserving capital and streamlining our organization.
+Added: As part of these changes (including the Lexington Facility sale and related employee transfers to Genezen), we expect to eliminate approximately 300 positions or 65% of our workforce.
+Added: We estimate that we will incur costs in the range of $6.5 million to $7.5 million in connection with the restructuring, consisting primarily of cash expenditures related to employee severance costs.
+Added: These costs are subject to assumptions, including local law requirements, and actual expenses may differ materially from the estimates disclosed above.
+Added: The restructuring is subject to the review by our Amsterdam-based works council, which is expected to be completed in the third quarter of 2024.
+Added: The Company expects the restructuring to be substantially completed by the end of 2024.
See the Exhibit Index immediately preceding the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
+Added: Asset Purchase Agreement, by and among uniQure Inc., uniQure biopharma B.V., Genezen Holdings Inc.
+Added: and Genezen MA, Inc., dated as of June 29, 2024.
+Added: Consent and Amendment No.
+Added: 2 to Loan and Security Agreement, dated June 28, 2024, by and among uniQure biopharma, B.V., uniQure, Inc., uniQure IP B.V., the Company and Hercules Capital, Inc.
+Added: Landlord Consent to Assignment and Assumption of Lease and Third Amendment to Lease, dated June 28, 2024, by and among Hartwell Innovation Campus, LLC, uniQure, Inc.
+Added: and Genezen MA, Inc.
+Added: Assignment and Assumption of Lease, dated July 22, 2024, by and between uniQure, Inc.
+Added: and Genezen MA, Inc.
+Added: Termination Agreement, dated July 22, 2024, by and between uniQure biopharma B.V.
+Added: and Pierre Caloz.
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
−Removed: The following financial information from our Quarterly Report on Form 10-Q for the period ended March 31, 2024, filed with the Securities and Exchange Commission on May 7, 2024, is formatted in Inline Extensible Business Reporting Language (“iXBRL”):
+Added: The following financial information from our Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024, is formatted in Inline Extensible Business Reporting Language (“iXBRL”):
(i) Consolidated Balance Sheets;
3 unchanged sentences
and (v) Notes to Consolidated Financial Statements (tagged as blocks of text)
−Removed: The cover page from our Quarterly Report on Form 10-Q for the period ended March 31, 2024, filed with the Securities and Exchange Commission on May 7, 2024, is formatted in Inline Extensible Business Reporting Language (“iXBRL”)
+Added: The cover page from our Quarterly Report on Form 10-Q for the period ended June 30, 2024, filed with the Securities and Exchange Commission on August 1, 2024, is formatted in Inline Extensible Business Reporting Language (“iXBRL”)
* Filed herewith.
1 unchanged sentence
t Indicates a management contract or compensatory plan or arrangement.
+Added: Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10)(iv).
+Added: Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
7 unchanged sentences
(Principal Financial Officer)
+Added: August 1, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.